Search For "eli lilly"
ABL Bio Receives Upfront Payment for License, Research and Collaboration A
Updated : 5 months, 1 week ago IST
Seoul [South Korea], December 26: ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform, and a USD 15 million equity inv
Read More
Piyush Goyal welcomes Eli Lilly's USD 1 billion investment in India
Updated : 7 months, 4 weeks ago IST
US-based pharmaceutical company Eli Lilly and Company has announced plans to invest more than USD one billion in India over the next several years, marking one of the largest foreign investments in the country's healthcare manufacturing sector in recent years. Union Minister of Commerce and
Read More
Eli Lilly plans to invest over USD 1 billion in new contract manufacturing
Updated : 8 months ago IST
In a major decision, US pharma giant Eli Lilly and Company (India) has said that it plans to invest more than $1 billion over the next several years into new contract manufacturing in India, expanding patients' access to innovative medicines aro
Read More
Celltrion signs agreement to buy Eli Lilly's U.S. plant for USD 330 mn
Updated : 8 months ago IST
South Korea's Celltrion Inc. has signed an agreement to acquire Eli Lilly and Company's U.S. biopharmaceutical manufacturing facility, eliminating its tariff-related risks in the U.S. market. The purchase price was USD 330 million, as per a report by Pulse, the English service of Maeil Busi
Read More
Lilly Partners with API to launch 'Obesity Gurukul' - a first-of its-kind
Updated : 8 months ago IST
Eli Lilly and Company (India), in collaboration with the Association of Physicians of India (API), on Friday announced the launch of 'API - Obesity Gurukul', a flagship Continuing Medical Education (CME) program aimed at enhancing physicians' clinical capabilities to address obesity, which
Read More
Weight loss drug Mounjaro shown more effective than Wegovy, claims Pharma
Updated : 1 year ago IST
Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide.
Read More
Lilly's orforglipron consistent with injectable GLP-1 medicines in Phase 3
Updated : 1 year, 1 month ago IST
According to an official statement from Eli Lilly and Company, "Orforglipron is the first oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3 trial."
Read More
Eli Lilly launches Mounjaro in India for anti obesity treatment
Updated : 1 year, 2 months ago IST
Approved by the Central Drugs Standard Control Organization (CDSCO), Mounjaro® is available in single-dose vials, with pricing set at Rs3,500 for a 2.5 mg vial and Rs4,375 for a 5 mg vial, leading to a monthly cost of Rs14,000-Rs17,500, depending on dosage.
Read More
'Eli Lilly' pharma company planning to expand research centre in India say
Updated : 1 year, 8 months ago IST
India is emerging as an economic superpower, highlighted David Ricks, CEO, Eli Lilly, a pharmaceutical company, following a roundtable interaction with PM Narendra Modi in New York on Sunday
Read More
Eli Lilly, Cipla enter in partnership to enhance access to Lilly's key dia
Updated : 4 years, 8 months ago IST
Mumbai (Maharashtra) [India], October 4 (ANI): Pharmaceutical firm Eli Lilly and Cipla entered into a strategic partnership in India to enhance access to Lilly's key diabetes products on Monday.
Read More
Eli Lilly's antibody cocktail drug gets emergency use nod in India
Updated : 5 years ago IST
New Delhi [India], June 1 (ANI): Eli Lilly and Company India on Tuesday announced that it has received emergency use approval in the country for its monoclonal antibody drug combination used for treating Covid-19 patients with mild to moderate symptoms.
Read More
Lilly India gets nod for use of monoclonal antibody drugs for treating Cov
Updated : 5 years ago IST
New Delhi [India], June 1 (ANI): Eli Lilly and Company India said on Tuesday it has received permission for restricted emergency use of its antibody drugs bamlanivimab 700 mg and etesevimab 1,400 mg in India for treatment of patients with mild to moderate coronavirus disease 2019 (Covid-19).
Read More